TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
|
|
|
||||
1. Identity of the issuer or the underlying issuer |
Immupharma plc |
||||
2 Reason for the notification (please tick the appropriate box or boxes): |
|||||
An acquisition or disposal of voting rights |
|
||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|
||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
||||
An event changing the breakdown of voting rights |
|
||||
Other (please specify): |
CHANGE IN NATURE: RETURN OF LOANED SHARES |
√ |
|||
3. Full name of person(s) subject to the |
Aviva plc & its subsidiaries |
||||
4. Full name of shareholder(s) |
Registered Holder:
BNY Norwich Union Nominees Limited 232,080* Chase (GA Group) Nominees Limited 6,977,654*
*denotes direct interest
Chase (GA Group) Nominees Limited 373,991
Chase Nominees Limited 150,841
Vidacos Nominees Limited 406,282
|
||||
5. Date of the transaction and date on |
19 January 2016 |
||||
6. Date on which issuer notified: |
20 January 2016 |
||||
7. Threshold(s) that is/are crossed or |
7% to 8% Change at Direct Interest Level (Box 8A) |
||||
8. Notified details: |
||||||||||
A: Voting rights attached to shares viii, ix |
||||||||||
Class/type of
|
Situation previous |
Resulting situation after the triggering transaction |
||||||||
Number |
Number |
Number |
Number of voting |
% of voting rights x |
||||||
Direct |
Direct xi |
Indirect xii |
Direct |
Indirect |
||||||
Ordinary Shares
GB0033711010 |
8,140,848* |
8,140,848* |
8,140,848 |
7,209,734 |
931,114 |
8.14% |
1.05% |
|||
|
||||||||||
*Includes right to recall loaned shares (168,000)
|
||||||||||
B: Qualifying Financial Instruments |
||||||||||
Resulting situation after the triggering transaction |
||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
||||||
|
|
|
|
|
||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi |
||||||
Resulting situation after the triggering transaction |
||||||
Type of financial |
Exercise price |
Expiration date xvii |
Exercise/ |
Number of voting rights instrument refers to
|
% of voting rights xix, xx
|
|
|
|
|
|
|
Nominal |
Delta |
|
|
Total (A+B+C) |
|
Number of voting rights |
Percentage of voting rights |
8,140,848 |
9.19% |
9. Chain of controlled undertakings through which the voting rights and/or the |
||
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-
Aviva Investors Global Services Limited: · Aviva plc (Parent Company) · Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) · Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) · Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
|
||
|
||
Proxy Voting: |
||
10. Name of the proxy holder: |
See Section 4 |
|
11. Number of voting rights proxy holder will cease |
|
|
12. Date on which proxy holder will cease to hold |
|
|
|
||
|
|
|
14. Contact name: |
Neil Whittaker, Aviva plc |
|
15. Contact telephone number: |
01603 684420 |
|